|
Active Pharmaceutical Ingredient Manufacturing
|
US$
300 |
|
Oct-2025 |
Doc　#43066 |
|
| Printed Page Length :
19
pages |
| Number of Tables :
3 |
| Number of Figures:
2 |
|
Market Overview
|
|
Taiwanese pharmaceutical companies will commission local API manufacturers to conduct pre-calibration batch trial production in the fourth quarter to qualify for preferential drug pricing under the National Health Insurance starting in 2026. Considering the limited impact of uncertain U.S. drug tariffs on the industry, the domestic API manufacturing sector is projected to maintain growth in the fourth quarter of 2025.
|
|
|
|